☰

Glenn J. Lesser, M.D. - Publications

Affiliations: 
Neurosurgery Wake Forest University School of Medicine, Winston-Salem, NC, United States 
Area:
GBM, cancer/oncogenesis, drugs/therapeutic agents
Website:
http://www.wakehealth.edu/faculty/lesser-glenn-j.htm
Tree Info Similar researchers PubMed Report error

140 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'Agostino RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, ... Lesser GJ, et al. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Scientific Reports. 10: 15195. PMID 32938997 DOI: 10.1038/S41598-020-72290-2  0.343
2020 Bower A, Hsu FC, Weaver KE, Yelton C, Merrill R, Wicks R, Soike M, Hutchinson A, McTyre E, Laxton A, Tatter S, Cramer C, Chan M, Lesser G, Strowd RE. Community economic factors influence outcomes for patients with primary malignant glioma. Neuro-Oncology Practice. 7: 453-460. PMID 32765895 DOI: 10.1093/Nop/Npaa010  0.312
2020 Fisher BJ, Pugh SL, Macdonald DR, Chakravatri A, Lesser GJ, Fox S, Rogers CL, Werner-Wasik M, Doyle T, Bahary JP, Fiveash JB, Bovi JA, Howard SP, Michael Yu HH, D'Souza D, et al. Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424. International Journal of Radiation Oncology, Biology, Physics. PMID 32251755 DOI: 10.1016/J.Ijrobp.2020.03.027  0.339
2020 Lycan TW, Hsu FC, Ahn CS, Thomas A, Walker FO, Sangueza OP, Shiozawa Y, Park SH, Peters CM, Romero-Sandoval EA, Melin SA, Sorscher S, Ansley K, Lesser GJ, Cartwright MS, et al. Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. Muscle & Nerve. PMID 32052458 DOI: 10.1002/Mus.26833  0.314
2020 Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, et al. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology. PMID 31974566 DOI: 10.1093/Neuonc/Noaa015  0.338
2020 Dent SF, Reding K, Lesser GJ, Klepin HD, Wagner LI, Kitzman D, Brubaker PH, Mihalko S, Avis NE, Winkfield KM, Ky B, Crotts T, Kikuchi R, Calhoun T, Hundley WG. Understanding and predicting fatigue, cardiovascular (CV) decline & events after breast cancer treatment (UPBEAT): A prospective multi-center wake forest NCORP research-base study. Journal of Clinical Oncology. 38: TPS602-TPS602. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps602  0.352
2020 Bell EH, Pugh SL, Fisher BJ, Lesser GJ, Macdonald DR, Fleming JL, McElroy JP, Becker AP, Rogers CL, Doyle TJ, Werner-Wasik M, Bahary J, Yu M, D'Souza D, Laack NN, et al. Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424. Journal of Clinical Oncology. 38: 2518-2518. DOI: 10.1200/Jco.2020.38.15_Suppl.2518  0.325
2019 Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert J, LaRocca R, O'Rourke DM, Fink K, Kim L, ... ... Lesser GJ, et al. A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31320597 DOI: 10.1158/1078-0432.Ccr-19-0261  0.318
2019 Cramer CK, Cummings TL, Andrews RN, Strowd R, Rapp SR, Shaw EG, Chan MD, Lesser GJ. Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients. Current Treatment Options in Oncology. 20: 42. PMID 30963289 DOI: 10.1007/S11864-019-0641-6  0.336
2019 Reding K, D'Agostino R, Lesser GJ, Klepin HD, Wagner LI, Kitzman D, Brubaker PH, Mihalko S, Jordan J, Avis NE, Winkfield KM, Ky B, Dent SF, Crotts T, Calhoun T, et al. Understanding and predicting fatigue, cardiovascular (CV) decline, and events after breast cancer treatment (UPBEAT): A prospective cardio-oncology study. Journal of Clinical Oncology. 37: TPS11634-TPS11634. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps11634  0.356
2019 Ahluwalia M, Dhruv H, Fallah J, Berens M, Drappatz J, Ye X, Lesser G, Cloughesy T, Walbert T, Holdhoff M, Peereboom D, Nabors L, Wen P, Grossman S, Rogers L. ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE EXCISION REPAIR INHIBITOR) IN BEVACIZUMAB-NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE Neuro-Oncology. 21: vi23-vi23. DOI: 10.1093/Neuonc/Noz175.085  0.366
2018 Strowd RE, Russell G, Hsu FC, Carter AF, Chan M, Tatter SB, Laxton AW, Alexander-Miller MA, High K, Lesser GJ. Immunogenicity of high-dose influenza vaccination in patients with primary central nervous system malignancy. Neuro-Oncology Practice. 5: 176-183. PMID 31385974 DOI: 10.1093/Nop/Npx035  0.307
2018 Cramer CK, Alphonse-Sullivan N, Isom S, Metheny-Barlow LJ, Cummings TL, Page BR, Brown DR, Blackstock AW, Peiffer AM, Strowd RE, Rapp S, Lesser GJ, Shaw EG, Chan MD. Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial. Journal of Cancer Research and Clinical Oncology. PMID 30417218 DOI: 10.1007/S00432-018-2791-5  0.396
2018 Wang A, Duncan SE, Lesser GJ, Ray WK, Dietrich AM. Effect of lactoferrin on taste and smell abnormalities induced by chemotherapy: a proteome analysis. Food & Function. PMID 30182113 DOI: 10.1039/C8Fo00813B  0.363
2018 Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE. Hypoxia-inducible factor 2α: a novel target in gliomas. Future Medicinal Chemistry. PMID 30089425 DOI: 10.4155/Fmc-2018-0163  0.307
2018 Hu JJ, Urbanic JJ, Case LD, Takita C, Wright JL, Brown DR, Langefeld CD, Lively MO, Mitchell SE, Thakrar A, Bryant D, Baglan K, Strasser J, Baez-Diaz L, Lesser GJ, et al. Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017771790. PMID 29989859 DOI: 10.1200/Jco.2017.77.1790  0.323
2018 Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, et al. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. Jama Oncology. PMID 29955793 DOI: 10.1001/Jamaoncol.2018.1977  0.361
2018 Ramkissoon LA, Britt N, Guevara A, Whitt E, Severson E, Sathyan P, Gay L, Elvin J, Ross JS, Brown C, Stogner-Underwood K, Mott R, Kram D, Strowd R, Lesser GJ, et al. Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas. Current Treatment Options in Oncology. 19: 41. PMID 29931654 DOI: 10.1007/S11864-018-0559-4  0.336
2018 Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, et al. Use of non-ionizing electromagnetic fields for the treatment of cancer. Frontiers in Bioscience (Landmark Edition). 23: 284-297. PMID 28930547 DOI: 10.2741/4591  0.328
2018 Lycan T, Thomas A, Hsu F, Cartwright MS, Walker FO, Ahn C, Sangueza OP, Shiozawa Y, Park SH, Peters CM, Melin SA, Avery TP, Sorscher S, Lesser GJ, Strowd RE. Neuromuscular ultrasound for assessment of peripheral neuropathy in breast cancer patients receiving taxane therapy. Journal of Clinical Oncology. 36: e22083-e22083. DOI: 10.1200/Jco.2018.36.15_Suppl.E22083  0.348
2018 Bower AS, Yelton C, Cramer C, Soike MH, McTyre E, Wicks R, Merrill R, Azagba S, Tatter SB, Laxton AW, Lesser GJ, Chan MD, Strowd RE. Community socioeconomic status to identify higher-risk patients with malignant glioma. Journal of Clinical Oncology. 36: 2060-2060. DOI: 10.1200/Jco.2018.36.15_Suppl.2060  0.364
2018 Albacker LA, Pavlick D, Ross JS, Lesser GJ, Corona RJ, Colman H, Groves MD, Hsu SH, Chi AS, Miller VA, Frampton GM, Ramkissoon S. Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas. Journal of Clinical Oncology. 36: 2039-2039. DOI: 10.1200/Jco.2018.36.15_Suppl.2039  0.325
2018 Ahluwalia M, Drappatz J, Ye X, Walbert T, Holdhoff M, Lesser G, Cloughesy T, Peereboom D, Burt Nabors L, Wen P, Grossman S, Rogers L. ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE Neuro-Oncology. 20: vi15-vi15. DOI: 10.1093/Neuonc/Noy148.052  0.317
2018 Fisher B, Zhang P, Macdonald D, Chakravarti A, Lesser G, Fox S, Coons S, Rogers L, Werner-Wasik M, Doyle T, Bahary J, Fiveash J, Bovi J, Howard S, Yu M, et al. ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS Neuro-Oncology. 20: vi11-vi11. DOI: 10.1093/Neuonc/Noy148.039  0.374
2018 Cramer CK, Wheless WH, McTyre E, Isom S, Hinson W, Rapp SR, Case LD, Cummings TL, Lesser GJ, Chan MD, Shaw EG, Whitlow CT, Peiffer AM. TRAIT (Treatment-Related Alterations in Thinking): A Prospective Longitudinal Study Assessing Mild Cognitive Impairment in Irradiated Brain Tumor Patients International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.07.037  0.33
2017 Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser G. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leukemia & Lymphoma. 1-7. PMID 29252084 DOI: 10.1080/10428194.2017.1410889  0.319
2017 Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, ... Lesser GJ, et al. Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02. Neuro-Oncology. PMID 29016887 DOI: 10.1093/Neuonc/Nox161  0.355
2017 Renfrow JJ, Strowd RE, Laxton AW, Tatter SB, Geer CP, Lesser GJ. Surgical Considerations in the Optimal Management of Patients with Malignant Brain Tumors. Current Treatment Options in Oncology. 18: 46. PMID 28681208 DOI: 10.1007/S11864-017-0487-8  0.35
2017 Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, et al. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro-Oncology. PMID 28371832 DOI: 10.1093/Neuonc/Nox020  0.313
2017 Meléndez GC, Sukpraphrute B, D'Agostino RB, Jordan JH, Klepin HD, Ellis L, Lamar Z, Vasu S, Lesser G, Burke GL, Weaver KE, Ntim WO, Hundley WG. Frequency of Left Ventricular End-Diastolic Volume-Mediated Declines in Ejection Fraction in Patients Receiving Potentially Cardiotoxic Cancer Treatment. The American Journal of Cardiology. PMID 28341361 DOI: 10.1016/J.Amjcard.2017.02.008  0.301
2017 McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. American Journal of Clinical Oncology. PMID 28301347 DOI: 10.1097/Coc.0000000000000380  0.348
2017 Datta M, Shaw EG, Lesser GJ, Case LD, Vitolins MZ, Schneider C, Frizzell B, Sullivan C, Lively M, Franzmann E, Hu JJ. A Randomized Double-Blind Placebo-Controlled Trial of Fruit and Vegetable Concentrates on Intermediate Biomarkers in Head and Neck Cancer. Integrative Cancer Therapies. 1534735416684947. PMID 28102098 DOI: 10.1177/1534735416684947  0.309
2017 Lesser GJ, Case D, Wang A, Dietrich A, Duncan S. A pilot study of lactoferrin in patients with self-reported, chemotherapy-induced taste and smell abnormalities. Journal of Clinical Oncology. 35: e21643-e21643. DOI: 10.1200/Jco.2017.35.15_Suppl.E21643  0.366
2016 Randolph DM, McTyre ER, Paulsson AK, Holmes JA, Hinson WH, Lesser GJ, Strowd R, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. Clinical Neurology and Neurosurgery. 151: 73-78. PMID 27816029 DOI: 10.1016/J.Clineuro.2016.10.012  0.367
2016 Gilbert MR, Rubinstein L, Lesser G. Creating clinical trial designs that incorporate clinical outcome assessments. Neuro-Oncology. 18: ii21-ii25. PMID 26989129 DOI: 10.1093/Neuonc/Nov254  0.314
2016 Yuan Y, Snyder BS, Russell GB, Lesser GJ. A clinical variable-based predictive model of delayed clearance of high dose methotrexate (HDMTX) in patients (pts) with primary CNS lymphoma (PCNSL). Journal of Clinical Oncology. 34: 2040-2040. DOI: 10.1200/Jco.2016.34.15_Suppl.2040  0.317
2016 Anderson SK, Miller CR, Sarkaria JN, Jaeckle KA, Buckner JC, Ligon KL, Ballman KV, Moore DF, Schiff D, Ahluwalia MS, Lee EQ, Horvath LE, Gerstner ER, Lesser GJ, Prados M, et al. Validating RNAseq-signatures of vorinostat (VOR) sensitivity and resistance in patients with newly diagnosed glioblastoma (GBM) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902. Journal of Clinical Oncology. 34: 2029-2029. DOI: 10.1200/Jco.2016.34.15_Suppl.2029  0.378
2016 Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty A, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, et al. Mpth-41. Mgmt Status Predicts Survival Outcomes In Nrg Oncology/Rtog 0424: A Phase Ii Trial Of Temozolomide-Based Chemoradiotherapy For High Risk Low-Grade Gliomas Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.478  0.331
2015 Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. Journal of Neuro-Oncology. 124: 447-53. PMID 26186902 DOI: 10.1007/S11060-015-1858-2  0.325
2015 Page BR, Shaw EG, Lu L, Bryant D, Grisell D, Lesser GJ, Monitto DC, Naughton MJ, Rapp SR, Savona SR, Shah S, Case D, Chan MD. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro-Oncology. PMID 25972454 DOI: 10.1093/Neuonc/Nov084  0.395
2015 Lucas JT, Huang AJ, Mott RT, Lesser GJ, Tatter SB, Chan MD. Anaplastic ganglioglioma: a report of three cases and review of the literature. Journal of Neuro-Oncology. 123: 171-7. PMID 25862009 DOI: 10.1007/S11060-015-1781-6  0.379
2015 Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, Ryu S, Werner-Wasik M, Bahary JP, Liu J, Chakravarti A, Mehta M. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. International Journal of Radiation Oncology, Biology, Physics. 91: 497-504. PMID 25680596 DOI: 10.1016/J.Ijrobp.2014.11.012  0.403
2015 Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 84: 280-6. PMID 25527270 DOI: 10.1200/Jco.2011.29.15_Suppl.2040  0.324
2015 Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, et al. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. Journal of Neuro-Oncology. 121: 297-302. PMID 25338318 DOI: 10.1007/S11060-014-1631-Y  0.393
2015 Mirlohi S, Duncan SE, Harmon M, Case D, Lesser G, Dietrich AM. Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors. Clinical Oral Investigations. 19: 127-37. PMID 24595687 DOI: 10.1007/S00784-014-1211-8  0.38
2015 Lewis JA, Petty WJ, Harmon M, Peacock JE, Valente K, Owen J, Pirmohamed M, Lesser GJ. Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 21: 220-3. PMID 24576944 DOI: 10.1177/1078155214524085  0.352
2015 Weaver KE, Urbanic JJ, Case D, Kaplan SG, Lesser GJ, Zbikowski S, Bryant D, Dakhil SR, Wilson C, Shaw EG, Danhauer S. Preliminary efficacy of an enhanced quitline smoking cessation intervention for cancer patients. Journal of Clinical Oncology. 33: e20671-e20671. DOI: 10.1200/Jco.2015.33.15_Suppl.E20671  0.329
2015 Qin R, Tan AD, Sloan JA, Johnson DR, Lesser GJ, Anderson SK, Laack NN. Quality of life analysis of NCCTG N0877 (Alliance): Phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E17715  0.395
2015 Urbanic JJ, Case D, Baez-Diaz L, Brown DR, Strasser J, Enevold G, Naughton M, Weaver KE, Baglan K, Bryant D, Langefeld C, Lad TE, Lee L, Rine G, Curtis AE, ... ... Lesser GJ, et al. A prospective evaluation of radiotherapy (RT) related skin reactions in a multi-racial/ethnic population of women with newly diagnosed breast cancer (BC). Journal of Clinical Oncology. 33: 6593-6593. DOI: 10.1200/Jco.2015.33.15_Suppl.6593  0.345
2015 Armstrong TS, Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, ... ... Lesser GJ, et al. Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107. Journal of Clinical Oncology. 33: 2036-2036. DOI: 10.1200/Jco.2015.33.15_Suppl.2036  0.405
2015 Holdhoff M, Ye X, Nabors LB, Desai AS, Mikkelsen T, Lesser G, Read WL, Lieberman FS, Supko J, Fisher JD, Desideri S, Grossman SA, Schiff D, Investigators A. Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium study. Journal of Clinical Oncology. 33: 2033-2033. DOI: 10.1200/Jco.2015.33.15_Suppl.2033  0.354
2015 Holdhoff M, Lodge MA, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Lieberman FS, Leal J, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, et al. NIMG-35RESULTS OF EXPLORATORY 18F-FLT PET IMAGING IN TEN RECURRENT HIGH-GRADE GLIOMA PATIENTS TREATED WITH THE SELECTIVE T-TYPE CALCIUM CHANNEL BLOCKER MIBEFRADIL FOLLOWED BY TEMOZOLOMIDE (ABTC TRIAL 1101) Neuro-Oncology. 17: v161.3-v161. DOI: 10.1093/Neuonc/Nov225.35  0.342
2015 Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, ... Lesser G, et al. Imct-20Association Of Survival And Progression-Free Survival With Immune Response In Hla-A2+ Newly-Diagnosed Gbm Patients In Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell (Dc) Immunotherapy With Ict-107 Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov218.20  0.345
2015 Urbanic J, Case D, Baez-Diaz L, Brown D, Strasser J, Enevold G, Naughton M, Weaver K, Baglan K, Bryant D, Langefeld C, Lad T, Lee L, Rine G, Curtis A, ... ... Lesser G, et al. Late Breast Toxicity Rates in a Prospective Evaluation of Radiation Therapy (RT) in a Multiracial/Ethnic Population of Breast Cancer (BC) Patients International Journal of Radiation Oncology*Biology*Physics. 93: E50-E51. DOI: 10.1016/J.Ijrobp.2015.07.670  0.318
2014 Attia A, Page BR, Lesser GJ, Chan M. Treatment of radiation-induced cognitive decline. Current Treatment Options in Oncology. 15: 539-50. PMID 25228143 DOI: 10.1007/S11864-014-0307-3  0.343
2014 Huang AJ, Huang KE, Page BR, Ayala-Peacock DN, Lucas JT, Lesser GJ, Laxton AW, Tatter SB, Chan MD. Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery. Journal of Neuro-Oncology. 120: 163-9. PMID 25048529 DOI: 10.1007/S11060-014-1539-6  0.346
2014 Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. Journal of Neuro-Oncology. 119: 429-35. PMID 24990827 DOI: 10.1007/S11060-014-1515-1  0.346
2014 Leyrer CM, Chan MD, Peiffer AM, Horne E, Harmon M, Carter AF, Hinson WH, Mirlohi S, Duncan SE, Dietrich AM, Lesser GJ. Taste and smell disturbances after brain irradiation: a dose-volume histogram analysis of a prospective observational study. Practical Radiation Oncology. 4: 130-5. PMID 24890354 DOI: 10.1016/J.Prro.2013.06.003  0.35
2014 Strowd RE, Swett K, Harmon M, Carter AF, Pop-Vicas A, Chan M, Tatter SB, Ellis T, Blevins M, High K, Lesser GJ. Influenza vaccine immunogenicity in patients with primary central nervous system malignancy. Neuro-Oncology. 16: 1639-44. PMID 24714522 DOI: 10.1093/Neuonc/Nou051  0.325
2014 Lawrence J, Griffin L, Rapp S, Messino MJ, Balcueva EP, Curtis AE, Groteluschen DL, Samuel TA, Lesser G, Case D, Shaw EG. Quality of life and cognitive dysfunction in breast cancer survivors on a feasibility study of donepezil versus placebo. Journal of Clinical Oncology. 32: 9516-9516. DOI: 10.1200/Jco.2014.32.15_Suppl.9516  0.32
2014 Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Smith KH, Gaffey SC, McCluskey CS, Ligon KL, Reardon DA, et al. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results. Journal of Clinical Oncology. 32: 2053-2053. DOI: 10.1200/Jco.2014.32.15_Suppl.2053  0.384
2014 Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle KA, Buckner JC, Ligon KL, Ballman KV, Moore DF, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, et al. Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902). Journal of Clinical Oncology. 32: 2030-2030. DOI: 10.1200/Jco.2014.32.15_Suppl.2030  0.391
2014 Norden AD, Drappatz J, Phuphanich S, Reardon DA, Wong ET, Plotkin SR, Kaley TJ, Raizer JJ, Lesser GJ, Batchelor T, Lee EQ, Beroukhim R, Muzikansky A, Doherty LM, LaFrankie DC, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results. Journal of Clinical Oncology. 32: 2027-2027. DOI: 10.1200/Jco.2014.32.15_Suppl.2027  0.412
2014 Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, Gruber ML, ... Lesser GJ, et al. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. Journal of Clinical Oncology. 32: 2005-2005. DOI: 10.1200/Jco.2014.32.15_Suppl.2005  0.366
2014 Strowd R, Russell G, Harmon M, Carter A, Chan M, Tatter S, Laxton A, High K, Lesser G. SM-07 * A PILOT STUDY OF HIGH-DOSE INFLUENZA VACCINE IMMUNOGENICITY IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANCY Neuro-Oncology. 16: v207-v207. DOI: 10.1093/Neuonc/Nou277.6  0.311
2014 Lesser G, Harmon M, Khan I, Whitlow C, Brown W. Bi-18Cellular Microparticles As Blood-Borne Endothelial Biomarkers In Patients With Malignant Gliomas Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou239.18  0.305
2014 Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, ... Lesser G, et al. At-60A Randomized Double Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell (Dc) Vaccine Ict-107 Following Standard Treatment In Newly Diagnosed Patients With Gbm Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.59  0.359
2014 Urbanic JJ, Case D, Lesser G, Enevold G, Naughton M, Danhauer S, Rapp S, Vitolins M, Johnson S, McCollough M, Duncan D, Papagikos M, Shaw EG. L-arginine–Based Nutritional Supplement Did Not Improve Erectile Function or Quality of Life in Prostate Cancer Survivors Previously Treated With Radiation Therapy: Results of CCOP Research Base Protocol 98110 – A Randomized Phase 2 Dose Finding Study International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.477  0.327
2013 Morrell RM, Tooze JA, Harmon MS, Carter AF, DeTroye AT, Lesser GJ. An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy. Journal of Oncology Practice / American Society of Clinical Oncology. 9: e268-71. PMID 23943891 DOI: 10.1200/Jop.2012.000834  0.317
2013 Renfrow JJ, Lesser GJ. Molecular subtyping of brain metastases and implications for therapy. Current Treatment Options in Oncology. 14: 514-27. PMID 23907440 DOI: 10.1007/S11864-013-0248-2  0.387
2013 Vincent A, Lesser G, Brown D, Vern-Gross T, Metheny-Barlow L, Lawrence J, Chan M. Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. Journal of Breast Cancer. 16: 122-6. PMID 23593093 DOI: 10.4048/Jbc.2013.16.1.122  0.38
2013 Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, et al. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro-Oncology. 15: 930-5. PMID 23553268 DOI: 10.1200/Jco.2011.29.15_Suppl.2038  0.332
2013 Strowd RE, Blackwood R, Brown M, Harmon M, Lovato J, Yalcinkaya T, Lesser G. Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 19: 321-7. PMID 23292971 DOI: 10.1177/1078155212469243  0.329
2013 Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. The Journal of Supportive Oncology. 11: 31-42. PMID 22682875 DOI: 10.1016/J.Suponc.2012.03.003  0.366
2013 Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Muzikansky A, Dietrich J, Smith KH, Gaffey SC, McCluskey CS, Ligon KL, Reardon DA, Wen PY. Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps2104  0.353
2013 Shaw EG, Case D, Bryant D, Grisell D, Lesser G, Monitto DC, Naughton MJ, Rapp SR, Savona SR, Shah S, Chan MD. Phase II double-blind placebo-controlled study of armodafinil for brain radiation induced fatigue. Journal of Clinical Oncology. 31: 9505-9505. DOI: 10.1200/Jco.2013.31.15_Suppl.9505  0.417
2013 Urbanic JJ, Case D, Naughton MJ, Hu JJ, Enevold G, Beech B, Weaver KE, Danhauer S, Rapp S, Sheidler V, Vitolins M, Lesser G, Shaw EG. Minority accrual on a prospective study targeting a diverse U.S. breast cancer population: An analysis of Wake Forest CCOP research base protocol 97609. Journal of Clinical Oncology. 31: 6564-6564. DOI: 10.1200/Jco.2013.31.15_Suppl.6564  0.309
2013 Fisher BJ, Lui J, Macdonald DR, Lesser GJ, Coons S, Brachman D, Ryu S, Werner-Wasik M, Bahary J, Hu C, Mehta MP. A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424. Journal of Clinical Oncology. 31: 2008-2008. DOI: 10.1200/Jco.2013.31.15_Suppl.2008  0.374
2012 Tooze J, Harmon M, Carter A, Detroye A, Lesser GJ. An automated system for insuring monitoring of myelosuppression in patients receiving self-administered oral chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 296. PMID 28147184 DOI: 10.1200/Jco.2012.30.34_Suppl.296  0.373
2012 Strowd RE, Knovich MA, Lesser GJ. The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies. Current Treatment Options in Oncology. 13: 451-64. PMID 22829388 DOI: 10.1007/S11864-012-0207-3  0.331
2012 Attia A, Rapp SR, Case LD, D’Agostino R, Lesser G, Naughton M, McMullen K, Rosdhal R, Shaw EG. Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. Journal of Neuro-Oncology. 109: 357-363. PMID 22700031 DOI: 10.1007/S11060-012-0901-9  0.394
2012 Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 118: 5601-7. PMID 22517399 DOI: 10.1002/Cncr.27585  0.45
2012 Renfrow JJ, Detroye A, Chan M, Tatter S, Ellis T, McMullen K, Johnson A, Mott R, Lesser GJ. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report. Journal of Neuro-Oncology. 107: 659-63. PMID 22249693 DOI: 10.1007/S11060-011-0788-X  0.393
2012 Geer CP, Simonds J, Anvery A, Chen MY, Burdette JH, Zapadka ME, Ellis TL, Tatter SB, Lesser GJ, Chan MD, McMullen KP, Johnson AJ. Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study. Ajnr. American Journal of Neuroradiology. 33: 556-62. PMID 22116105 DOI: 10.3174/Ajnr.A2811  0.31
2012 Ruiz J, Case D, Enevold G, Rosdhal R, Tatter SB, Ellis TL, McQuellon RP, McMullen KP, Stieber VW, Shaw EG, Lesser GJ. A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. Journal of Neuro-Oncology. 106: 611-7. PMID 21870118 DOI: 10.1007/S11060-011-0698-Y  0.412
2012 Hawkins ES, Aiken R, Chandler J, Fink KL, Glantz MJ, Grewal J, Gruber ML, Kesari S, Landolfi JC, LaRocca RV, Lesser GJ, Markert J, Mayer TM, O'Rourke D, Peereboom DM, et al. A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2107  0.392
2012 Leyrer M, Chan M, Peiffer A, Horne E, Harmon M, Carter A, Hinson W, Duncan S, Dietrich A, Lesser G. Radiation-induced Taste and Smell Toxicity: A Dose-Volume Histogram Analysis of a Prospective Observational Study International Journal of Radiation Oncology*Biology*Physics. 84: S302. DOI: 10.1016/J.Ijrobp.2012.07.789  0.402
2011 Lesser GJ, Case LD, Mirlohi S, Harmon M, Chan M, Duncan S, Dietrich A. Taste and smell abnormalities (TSA) in patients with newly diagnosed malignant gliomas (MG) treated with combined modality therapy (CMT). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e19646. PMID 28021818 DOI: 10.1200/Jco.2011.29.15_Suppl.E19646  0.388
2011 Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5473-80. PMID 21737504 DOI: 10.1158/1078-0432.Ccr-11-0774  0.33
2011 Lamar Z, Lesser GJ. Management of meningeal neoplasms: meningiomas and hemangiopericytomas. Current Treatment Options in Oncology. 12: 230-9. PMID 21537847 DOI: 10.1007/S11864-011-0156-2  0.362
2011 Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 76: 929-30. PMID 21383331 DOI: 10.1212/Wnl.0B013E31820F2D94  0.348
2011 Chan MD, Attia A, Tatter SB, Lesser G, Zapadka ME, Mott RT, Carter A, McMullen KP, Shaw EG, Ellis TE. Radiation-induced adult medulloblastoma: a two-case report and review of the literature. Journal of Neuro-Oncology. 103: 745-9. PMID 20936325 DOI: 10.1007/S11060-010-0426-Z  0.34
2010 Chan MD, Tatter SB, Lesser G, Shaw EG. Radiation oncology in brain tumors: current approaches and clinical trials in progress. Neuroimaging Clinics of North America. 20: 401-8. PMID 20708554 DOI: 10.1016/J.Nic.2010.04.005  0.414
2010 Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro-Oncology. 12: 1071-7. PMID 20615924 DOI: 10.1093/Neuonc/Noq071  0.428
2010 Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Mikkelson T, Fisher J, Desideri S, He X, Grossman SA. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. Journal of Neuro-Oncology. 100: 261-8. PMID 20449631 DOI: 10.1007/S11060-010-0190-0  0.411
2010 Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson JJ. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma Journal of Neuro-Oncology. 100: 95-103. PMID 20213332 DOI: 10.1007/S11060-010-0143-7  0.36
2010 Case LD, Naughton MJ, Lesser GJ, Rapp SR, Vitolins M, Sheidler VR, Enevold GL, Shaw EG. Recruitment and retention in the Wake Forest University CCOP Research Base. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E19543  0.305
2010 Vitolins M, Lesser GJ, Case LD, Williford SK, Giguere JK, Garino A, Naughton MJ, Lively M, Melin SA, Shaw EG. Self-reported compliance compared to biomarker levels of vitamin E in breast cancer patients participating in a CoQ10 clinical trial. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E19524  0.313
2010 Attia A, Case LD, D'Agostino R, Lesser GJ, McMullen K, Naughton MJ, Rapp SR, Rosdhal R, Shaw EG. Phase II study of ginkgo biloba in irradiated brain tumor survivors: Effects on quality of life (QOL), mood, and cognitive function. Journal of Clinical Oncology. 28: e12523-e12523. DOI: 10.1200/Jco.2010.28.15_Suppl.E12523  0.397
2010 Naughton MJ, Case LD, Meyers CA, Loghin ME, Shaw EG, Saphner TJ, Sleckman BG, Giguere JK, Lesser GJ, Rapp SR. Quality of life (QOL) and cognitive performance among irradiated brain cancer patients. Journal of Clinical Oncology. 28: 9131-9131. DOI: 10.1200/Jco.2010.28.15_Suppl.9131  0.327
2010 Lesser GJ, Case LD, Stark N, Williford SK, Giguere JK, Garino A, Naughton MJ, Vitolins M, Lively M, Shaw EG. A randomized double-blind placebo-controlled study of oral coenzyme Q10 to relieve self-reported cancer-treatment-related fatigue in newly diagnosed breast cancer patients. Journal of Clinical Oncology. 28: 9006-9006. DOI: 10.1200/Jco.2010.28.15_Suppl.9006  0.361
2010 High KP, Case LD, Siegel RD, Metzner-Sidurski J, Krauss JC, Chinnasami B, Sanders GH, Rousey S, Lesser GJ, Shaw EG. A phase III randomized, double-blind, placebo controlled trial of North American (NA) ginseng (Panax quinquefolium) extract (CVT-E002) in patients with chronic lymphocytic leukemia: Effect on respiratory infection and antibiotic use. Journal of Clinical Oncology. 28: 6578-6578. DOI: 10.1200/Jco.2010.28.15_Suppl.6578  0.333
2010 Calipari ES, Tallant EA, Lesser G, Debinski W, Gallagher PE. Abstract 3575: Angiotensin-(1-7) and temozolomide provide combinatorial inhibition of glioblastoma cell growth Cancer Research. 70: 3575-3575. DOI: 10.1158/1538-7445.Am10-3575  0.355
2010 Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Fisher J, Desideri S, He X, Grossman SA. Erratum to: A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas (Journal of Neuro-Oncology DOI: 10.1007/s11060-010-0190-0) Journal of Neuro-Oncology. 100. DOI: 10.1007/S11060-010-0234-5  0.361
2009 Ruiz J, Lesser GJ. Low-grade gliomas. Current Treatment Options in Oncology. 10: 231-42. PMID 19381819 DOI: 10.1007/S11864-009-0096-2  0.445
2008 Lustig R, Mikkelsen T, Lesser G, Grossman S, Ye X, Desideri S, Fisher J, Wright J. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease Neuro-Oncology. 10: 1004-1009. PMID 18725460 DOI: 10.1215/15228517-2008-070  0.42
2008 Grossman SA, Carson KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG. Phase i and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas Neuro-Oncology. 10: 608-616. PMID 18577560 DOI: 10.1215/15228517-2008-030  0.383
2008 Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro-Oncology. 10: 617-23. PMID 18477765 DOI: 10.1215/15228517-2008-013  0.414
2008 Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro-Oncology. 10: 190-8. PMID 18287342 DOI: 10.1215/15228517-2007-055  0.418
2008 Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Current Treatment Options in Oncology. 9: 23-31. PMID 18247132 DOI: 10.1007/S11864-008-0053-5  0.334
2008 Lesser GJ, Case D, Ottery F, McQuellon R, Choksi JK, Sanders G, Rosdhal R, Shaw EG. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy Journal of Clinical Oncology. 26: 9513-9513. DOI: 10.1200/Jco.2008.26.15_Suppl.9513  0.356
2007 Butler JM, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, Lesser G, McMullen K, McQuellon R, Naughton M, Rapp S, Stieber V, Shaw EG. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 69: 1496-501. PMID 17869448 DOI: 10.1016/J.Ijrobp.2007.05.076  0.37
2007 Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 2: 445-9. PMID 17473661 DOI: 10.1097/01.Jto.0000268679.33238.67  0.403
2007 Lesser GJ, Stieber V, Case D, Enevold G, Rosdhal R, Tatter S, Ellis T, McMullen K, Shaw E. A phase II trial of thalidomide (Thal) and procarbazine (Pro) in adults with recurrent or progressive malignant gliomas (MG) Journal of Clinical Oncology. 25: 2067-2067. DOI: 10.1200/Jco.2007.25.18_Suppl.2067  0.342
2006 Peacock KH, Lesser GJ. Current therapeutic approaches in patients with brain metastases. Current Treatment Options in Oncology. 7: 479-89. PMID 17032560 DOI: 10.1007/S11864-006-0023-8  0.424
2006 Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5174-81. PMID 16951236 DOI: 10.1158/1078-0432.Ccr-06-0932  0.335
2006 Lesser GJ, Case D, Sharp S, Choksi J, Miller A, Atkins JN, Shaw E. A Phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo) Journal of Clinical Oncology. 24: 18546-18546. DOI: 10.1200/Jco.2006.24.18_Suppl.18546  0.334
2005 Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Does phenytoin does affect celecoxib pharmacokinetics in patients with newly diagnosed glioblastoma multiforme? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2085. PMID 27946645 DOI: 10.1200/Jco.2005.23.16_Suppl.2085  0.372
2005 Farmer M, Case D, Lesser G, Monitto D, Smathers S, May B, Allison R, Naughton M, McQuellon R, Blackstock W, Greven K, Shaw EG. A Phase III, Double Blind, Placebo-Controlled, Prospective Randomized Trial on the Effect of Megestrol Acetate on Weight and Health Related Quality of Life in Lung Cancer and Head and Neck Cancer Patients Receiving Curative Radiation Therapy International Journal of Radiation Oncology Biology Physics. 63. DOI: 10.1016/J.Ijrobp.2005.07.133  0.359
2004 Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Current Treatment Options in Oncology. 5: 511-7. PMID 15509484 DOI: 10.1007/S11864-004-0039-X  0.362
2004 Shaw EG, Tatter SB, Lesser GJ, Ellis TL, Stanton CA, Stieber VW. Current controversies in the radiotherapeutic management of adult low-grade glioma. Seminars in Oncology. 31: 653-8. PMID 15497118 DOI: 10.1053/J.Seminoncol.2004.07.007  0.41
2004 Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5643-6. PMID 15355887 DOI: 10.1158/1078-0432.Ccr-04-0159  0.362
2004 Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-Oncology. 6: 21-7. PMID 14769136 DOI: 10.1215/S1152851703000218  0.415
2004 Laterra JJ, Grossman SA, Carson KA, Lesser GJ, Hochberg FH, Gilbert MR. Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro-Oncology. 6: 15-20. PMID 14769135 DOI: 10.1215/S1152851703000127  0.444
2004 Peereboom D, Carson K, Lawson D, Lesser G, Supko J, Grossman S. A phase I/II trial of BMS-247550 for patients with recurrent high-grade gliomas Journal of Clinical Oncology. 22: 1546-1546. DOI: 10.1200/Jco.2004.22.90140.1546  0.369
2004 Stieber V, Tatter S, Lovato J, Ellis T, deGuzman A, Hinson W, Kearns W, Bourland J, Rosdahl R, Lesser G, Stanton C, Shaw E. A Phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) International Journal of Radiation Oncology*Biology*Physics. 60: S261. DOI: 10.1016/J.Ijrobp.2004.07.037  0.335
2003 Yalamanchili M, Lesser GJ. Malignant spinal cord compression. Current Treatment Options in Oncology. 4: 509-16. PMID 14585231 DOI: 10.1007/S11864-003-0051-6  0.322
2003 Blackstock AW, Case LD, Ho C, Tucker R, Lesser G, Miller AA. P-599 Gemcitabine and concurrent thoracic radiotherapy - A phase I/II study in patients with advanced non-small cell lung cancer (NSCLC) Lung Cancer. 41. DOI: 10.1016/S0169-5002(03)92566-9  0.329
2003 Miller AA, Tucker R, Lesser G, Case D. P-563 Phase I study of sequential topotecan-carboplatin-etoposide in patients with Extensive Disease Small Cell Lung Cancer (ED-SCLC) Lung Cancer. 41. DOI: 10.1016/S0169-5002(03)92530-X  0.308
2002 Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. Journal of Neuro-Oncology. 57: 231-9. PMID 12125986 DOI: 10.1023/A:1015752331041  0.377
2002 McMullen KP, Miller AA, Case LD, Lesser G, Culbreth M, Patton S, Tucker R, Blackstock AW. Thoracic radiation and concurrent gemcitabine: a phase I/II study in patients with advanced non-small cell lung cancer (NSCLC) International Journal of Radiation Oncology Biology Physics. 54: 297. DOI: 10.1016/S0360-3016(02)03571-X  0.334
2001 Blackstock AW, Lesser GJ, Fletcher-Steede J, Case LD, Tucker RW, Russo SM, White DR, Miller A. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 51: 1281-9. PMID 11728688 DOI: 10.1016/S0360-3016(01)01732-1  0.378
2001 Lesser GJ. Chemotherapy of low-grade gliomas. Seminars in Radiation Oncology. 11: 138-44. PMID 11285551 DOI: 10.1053/Srao.2001.21422  0.422
2001 Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, ... ... Lesser G, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. British Journal of Cancer. 84: 157-63. PMID 11161370 DOI: 10.1054/Bjoc.2000.1574  0.404
2000 Blackstock AW, Acostamadiedo J, Lesser G, Richards F, Case LD, White DR. Phase II study of pyrazine diazohydroxide (NSC 361456) for advanced non small-cell lung cancer. Clinical Lung Cancer. 2: 62-6. PMID 14731342 DOI: 10.3816/Clc.2000.N.019  0.425
2000 Tassler P, Dellon AL, Lesser GJ, Grossman S. Utility of decompressive surgery in the prophylaxis and treatment of cisplatin neuropathy in adult rats. Journal of Reconstructive Microsurgery. 16: 457-63. PMID 10993092 DOI: 10.1055/S-2006-947153  0.317
2000 Kleinberg L, Grossman S, Carson K, Lesser G, O'Neill A, Pearlman J, Phillips P, Herman T, Gerber M. Mature phase II results suggest a survival benefit of RSR13 combined with standard cranial radiotherapy in patients with newly diagnosed glioblastoma multiforme International Journal of Radiation Oncology*Biology*Physics. 48: 202-203. DOI: 10.1016/S0360-3016(00)80199-6  0.376
1999 Lesser G, Kleinberg L, Grossman S, Piantadosi S, O'Neill A, Pearlman J, Phillips P, Herman T, Gerber M. 1017 Initial results of a phase II trial of RSR13, a new radioenhancer, in newly diagnosed glioblastoma (GBM) International Journal of Radiation Oncology*Biology*Physics. 45: 266. DOI: 10.1016/S0360-3016(99)90243-2  0.304
1996 Lesser GJ. Chemotherapy of cerebral metastases from solid tumors. Neurosurgery Clinics of North America. 7: 527-36. PMID 8823780 DOI: 10.1016/S1042-3680(18)30378-4  0.404
1993 Lesser GJ, Grossman SA. The chemotherapy of adult primary brain tumors. Cancer Treatment Reviews. 19: 261-81. PMID 8392909 DOI: 10.1016/0305-7372(93)90038-S  0.324
Show low-probability matches.